Pertuzumab

Metastatic Breast Cancer
Pertuzumab is indicated, in combination with trastuzumab and docetaxel, for patients with HER2-positive metastatic or locally recurrent inoperable breast cancer who have not previously received anti-HER2 therapy or chemotherapy for metastatic disease.

Early-Stage Breast Cancer
Pertuzumab is indicated, in combination with trastuzumab and chemotherapy*, for:

Neoadjuvant treatment of patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer at high risk of recurrence (defined as either a tumor diameter > 2 cm or positive lymph nodes) as part of a comprehensive treatment regimen for early-stage breast cancer.

Adjuvant treatment of patients with early-stage HER2-positive breast cancer at high risk of recurrence.